Compare Amgen, Inc. (AMGN) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Financial Select Sector SPDR Fund — how do they compare? Amgen, Inc. trades at $356.4 (market cap $196.12B), while Financial Select Sector SPDR Fund trades at $55.7. The key difference: Amgen, Inc. pays a 2.77% dividend while Financial Select Sector SPDR Fund pays none, and Financial Select Sector SPDR Fund is trading nearer its 52-week high, Amgen, Inc. nearer its low. Which is the better fit depends on your goals.
| AMGN | XLF | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $56.41 |
52-Week Low | $271.18 | $47.80 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
XLF trades at $55.71, up 0.31% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX readings above 55. The ETF is positioned ahead of Q2 bank earnings reports, with news highlighting potential benefits from Federal Reserve rate hikes and recent dividend increases following positive stress test results. Support rests near $55, with resistance at $56.
Outlook is cautiously optimistic as financial sector strength and higher interest rates could drive gains, though overbought RSI levels and geopolitical tensions pose near-term risks. Investor focus remains on earnings performance and macroeconomic policy shifts for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
